Serum ANGPTL8 levels were significantly lower (p = 0.001) in NAFLD patients (1940.0 ± 90.0† pg/mL) compared to controls (2340.0 ± 60.0† pg/mL). The mild fibrosis group (fibrosis score less than 2) had higher serum ANGPTL8 levels than the significant fibrosis group (fibrosis score of 2 or greater), and so ANGPTL8 levels tend to decrease when the disease progresses. The gene discussed is ANGPTL8; the disease is metabolic dysfunction-associated steatotic liver disease.